LaClair, Katherine D.
Zhou, Qihui
Michaelsen, Meike
Wefers, Benedikt
Brill, Monika S.
Janjic, Aleksandar
Rathkolb, Birgit
Farny, Daniel
Cygan, Mikolaj
de Angelis, Martin Hrabe
Wurst, Wolfgang
Neumann, Manuela
Enard, Wolfgang
Misgeld, Thomas
Arzberger, Thomas
Edbauer, Dieter http://orcid.org/0000-0002-7186-4653
Funding for this research was provided by:
NOMIS Stiftung
Deutsche Forschungsgemeinschaft (EXC 2145 / ID 390857198, FOR 2879 (Mi694/9-1), TRR274 (B03, C02))
FP7 Ideas: European Research Council (617198, 616791)
Deutsche Forschungsgemeinschaft (CRC870 (A11))
Bundesministerium für Bildung und Forschung (Infrafrontier grant 01KX1012)
German Center for Diabetes Research
Article History
Received: 22 April 2020
Revised: 4 June 2020
Accepted: 4 June 2020
First Online: 19 June 2020
Compliance with ethical standards
:
: DE and TA hold a patent (US10066007B2) on “Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion”. DE and QZ applied for a patent on active vaccination targeting DPRs in <i>C9orf72</i> ALS/FTD.